PMC:7291971 / 8731-9097
Annnotations
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T170 | 15-28 | SO:0000409 | denotes | binding sites |
| T171 | 41-46 | PR:000000125 | denotes | nsp14 |
| T172 | 87-95 | SP_10 | denotes | SARS-CoV |
| T173 | 100-110 | SP_7 | denotes | SARS-CoV-2 |
| T174 | 125-133 | SO:0000857 | denotes | homology |
| T175 | 246-254 | SP_10 | denotes | SARS-CoV |
| T176 | 305-315 | SP_7 | denotes | SARS-CoV-2 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T45 | 11-14 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T28 | 87-95 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T29 | 100-108 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T30 | 246-254 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T31 | 305-313 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T65 | 156-158 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
| T66 | 161-163 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T101 | 3-6 | Chemical | denotes | SAM | http://purl.obolibrary.org/obo/CHEBI_15414|http://purl.obolibrary.org/obo/CHEBI_67040 |
| T103 | 201-208 | Chemical | denotes | ligands | http://purl.obolibrary.org/obo/CHEBI_52214 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T59 | 0-366 | Sentence | denotes | As SAM and RNA binding sites of N7-MTase nsp14 are almost completely conserved between SARS-CoV and SARS-CoV-2 (95% sequence homology, Supporting Info Fig. S1) [18], we can forecast that the candidate ligands that are efficient in inhibiting the SARS-CoV functions will be efficient in doing the same for SARS-CoV-2, this emphasizes the interest of the present work. |